BIOMAT Database Logo BIOMAT Database Logo

Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). 1988

T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.

Various 3'-azido analogues of pyrimidine deoxyribonucleosides have been synthesized and tested against human immunodeficiency virus (HIV-1, HTLV-III/LAV) in human peripheral blood mononuclear cells. Among these compounds, the 3'-azido analogues of thymidine (2), 3-(3-oxo-1-propenyl)thymidine (21), 2'-deoxyuridine (1), 2'-deoxy-5-bromouridine(5), 2'-deoxy-5-fluorocytidine (19), 2'-deoxy-5-iodouridine (6), 2'-deoxycytidine (18), 2'-deoxy-5-fluorouridine (4), 2'-deoxy-5-thiocyoanatouridine (16), 2'-deoxy-5-methylcytidine (20), 2'-deoxy-5-aminouridine (7), and 2'-deoxy-5-hydroxyuridine (10) were found to have significant antiviral activity, with EC50 values of 0.002, 0.01, 0.2, 1.0, 1.0, 1.1, 1.2, 4.8, 5.1, 5.1, 6.2, and 10 microM, respectively. The structure-activity relationships are discussed.

UI MeSH Term Description Entries
D011741 Pyrimidine Nucleosides Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. Nucleosides, Pyrimidine
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Synthesis and antiviral activity of monofluoro and difluoro analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1).
August 1990, Journal of medicinal chemistry,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
February 1987, Journal of medicinal chemistry,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Synthesis and biological activity of various 3'-azido and 3'-amino analogues of 5-substituted pyrimidine deoxyribonucleosides.
December 1983, Journal of medicinal chemistry,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
2'-azido-2',3'-dideoxypyrimidine nucleosides. Synthesis and antiviral activity against human immunodeficiency virus.
June 1990, Journal of medicinal chemistry,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
[The genome of HIV (HTLV-III, LAV), the human immunodeficiency virus].
January 1987, Postepy biochemii,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Transmission of human immunodeficiency virus (HIV/HTLV-III/LAV): a review.
January 1986, Infection,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Antiviral chemotherapies directed against HTLV-III/LAV.
December 1986, The Mount Sinai journal of medicine, New York,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Antiviral chemotherapy against HTLV-III/LAV infections.
May 1986, The Journal of antimicrobial chemotherapy,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV).
December 1988, Gene,
T S Lin, and J Y Guo, and R F Schinazi, and C K Chu, and J N Xiang, and W H Prusoff
Antiviral strategies and vaccines against HTLV III/LAV.
October 1986, Journal of the Royal College of Physicians of London,
Copied contents to your clipboard!